Canonical: https://neurodiversity.gklijs.tech/i/2571e4af3090

# Scaling up n-of-1 trials; and more

Spectrum (The Transmitter)

17 November 2026 (2026-11-17)

A new study outlines a method to scale up genetic therapies tested in n-of-1 trials by using gene-specific haplotyping to identify compatible patients for antisense oligonucleotides targeting SCN2A variants. The approach aims to prequalify a set of oligonucleotides that address the most common causal mutations, potentially expanding access to these therapies. This strategy could help move personalized genetic treatments from individual cases to broader applications.

[Read at Spectrum (The Transmitter)](<https://www.thetransmitter.org/spectrum/scaling-up-n-of-1-trials-and-more/>)

All articles from [17 November 2026](</2026/11/17>). Summaries are AI-generated and may contain errors; the linked article is the authority.

## Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the [subscribe page](</subscribe>).

## More to read

- [Topics](</topics>)
- [Agenda](</agenda>)
- [Subscribe](</subscribe>)
